N,N-dimethyl-1-(5-methylpyrimidin-2-yl)piperidin-4-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dimethyl-1-(5-methylpyrimidin-2-yl)piperidin-4-amine
• 化学式: C₁₂H₂₀N₄
• 分子量: 220.31
• InChiKey: HROAPBYDLOBHFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES
  申请人：FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA

  公开号：US20160002246A1

  公开（公告）日：2016-01-07

  It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B 1 is a radical selected from the group consisting of formula (A″), formula (B″), formula (C″), and formula (D″):

  它涉及到一些具有多环结构和羟胺酸基团的化合物，其中多环结构包括至少三个环系统，其中一个环系统是由2至4个环组成的多环环系统；至少一个环是芳香环；结构中包含至少3个氮原子和1个氧原子。它还涉及到它们的制备过程，以及包含它们的制药组合物，以及它们在医学上的应用，特别是在治疗和/或预防伴随认知缺陷或损伤或神经退行性疾病的神经系统疾病中。其中B1是从公式（A''）、公式（B''）、公式（C''）和公式（D''）组成的基团。
• Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
  申请人：Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

  公开号：US10647687B2

  公开（公告）日：2020-05-12

  The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

  本发明涉及作为非凋亡调节细胞死亡抑制剂的螺吡嗪化合物，以及含有此类化合物的药物组合物。此外，本发明还涉及此类化合物和药物组合物在治疗中的用途，特别是在治疗以非凋亡调节性细胞死亡为特征或非凋亡调节性细胞死亡可能起作用或起重要作用的病症、紊乱或疾病中的用途。本文所述的化合物和药物组合物还可用于治疗以氧化应激为特征的病症、紊乱或疾病，或氧化应激可能起作用或起重要作用的病症、紊乱或疾病；和/或(1)坏死体的一种或多种成分；(2)死亡结构域受体；和/或(3)Toll 样受体；和/或(4)铁变态反应/铁变态反应信号的参与者，或(1)至(3)和/或(4)中任何一种的激活可能起或起重要作用的情况、紊乱或疾病。
• US9573956B2
  申请人：——

  公开号：US9573956B2

  公开（公告）日：2017-02-21
• [EN] NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES<br/>[FR] NOUVEAUX COMPOSÉS COMME INHIBITEURS DOUBLE DE PHOSPHODIESTÉRASES ET D'HISTONES DÉACÉTYLASES
  申请人：FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLIC

  公开号：WO2014131855A1

  公开（公告）日：2014-09-04

  It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):